Drug Profile


Alternative Names: GP-205

Latest Information Update: 02 May 2016

Price : $50

At a glance

  • Originator Ginkgo Pharma
  • Class Antivirals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hepatitis C

Most Recent Events

  • 10 Mar 2016 Ginkgo Pharma has patent protection for seraprevir in USA
  • 28 Jan 2016 Phase-I clinical trials in Hepatitis C in China (unspecified route) (ChiCTR-IIC16007978)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top